Teng et al. tested on the HER2+ CRC PDX model the efficacy of HER2-specific CAR-T cells that infiltrate into the tumor, selectively eliminated the HER2+ cells causing the decrease in tumor size and the complete tumor elimination after 2 months from treatment [125]. Here, ERBB2 is linked to colorectal carcinoma.